A commentary on “Comparison of efficacy and safety between neoadjuvant chemotherapy and neoadjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis”

aDepartment of Pharmacy, the First People's Hospital of Shangqiu, Henan, 476100, PR China bDepartment of Gastroenterology, the First People's Hospital of Shangqiu, Henan, 476100, PR China cDepartment of Emergency Intensive Care Unit, the First People's Hospital of Shangqiu, Henan, 476100, PR China Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: E-mail address: [email protected] (D. Ge) This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/